Chordia Therapeutics Inc.
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
ir@chordiatherapeutics.com

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>
25th April 2025

Company: Chordia Therapeutics, Inc
Representative: Chief Executive Officer Hiroshi Miyake
(Security Code: 190A TSE Growth Market)
Contact: IR Representative Ami Kira

Chordia presents new data at the American Association for Cancer Research Annual Meeting 2025

Kanagawa Japan

25th April 2025 – Chordia Therapeutics Inc. (Head Office: Fujisawa City, Kanagawa Prefecture; CEO: Hiroshi Miyake) announces that Chordia presents new data of CDK12 inhibitor CTX-439 and GCN2 inhibitor at the American Association for Cancer Research (AACR) Annual Meeting, April 25-30, 2025, in Chicago, Illinois.

Two presentations will be given on Chordia's pipeline of CDK12 inhibitor CTX-439, and a GCN2 inhibitor.

Presentation Summary

<CDK12 inhibitor: CTX-439>

Our CDK12 inhibitor, CTX-439, has demonstrated promising new potential for cancer therapy. CTX-439 suppresses the production of MCL1, a protein critical for cancer cell survival, and exhibits marked antitumor activity when combined with a BCL-2/BCL-xL inhibitor. These findings significantly broaden the clinical potential of CTX-439 and highlight its promise as a new therapeutic option for refractory triple-negative breast cancer and other indications.

<GCN2 Inhibitor>

Our HRI/PERK/GCN2 inhibitor, CRD-799, has shown potential as a novel therapeutic option for the treatment of refractory multiple myeloma. CRD-799, in combination with existing proteasome inhibitors, demonstrated clear anti-tumor efficacy. In this combination therapy, CRD-799 controls the stress response pathway in cancer cells and induces cell death, which is the mechanism underlying its antitumor effects. These findings expand the potential clinical applications of CRD-799.

Chordia Therapeutics Inc.
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
ir@chordiatherapeutics.com

Presentation on CTX-439, CDK12 inhibitor

Abstract No	1636
Title	Novel CDK12/13 inhibitor CTX-439 downregulates MCL1 via transcriptional mRNA read-through and synergistically acts with BCL-XL inhibitors for cancer therapy

Presentation on GCN2 inhibitor

Abstract No	1745
Title	Combining HRI/PERK/GCN2 inhibitor CRD-799 with proteasome inhibitors provides a novel approach to overcoming resistance in multiple myeloma treatment

About Chordia Therapeutics

Chordia is a clinical stage biotech company based in Fujisawa, Kanagawa Prefecture, Japan, engaged in the research and development of novel therapies for cancers.
Chordia's lead asset, rogocekib (CLK inhibitor CTX-712), is under Phase 1/2 clinical study in the US. rogocekib potentially targets the vulnerability of cancer and is expected to deliver benefits to patients of various types of cancer. In addition to rogocekib, Chordia is engaged in the research of several preclinical assets, including CTX-439, a CDK12 inhibitor, which is expected to be effective in cancers with specific abnormalities, as well as GCN2 inhibitors. For more information, please contact our website https://www.chordiatherapeutics.com/en/.